Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
C4 Therapeutics, Inc. - Common Stock
(NQ:
CCCC
)
6.320
-0.110 (-1.71%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about C4 Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple
October 11, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Announces Chief Financial Officer Succession
September 05, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 08, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Inc. (NASDAQ: CCCC) Highlighted for Surprising Price Action
May 30, 2023
Via
Investor Brand Network
The Latest Analyst Ratings for C4 Therapeutics
May 30, 2023
Via
Benzinga
Looking Into C4 Therapeutics's Return On Capital Employed
May 18, 2023
Via
Benzinga
Expert Ratings for C4 Therapeutics
May 08, 2023
Via
Benzinga
C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
July 06, 2023
Via
Benzinga
Nasdaq Edges Lower Following Fed Minutes; C4 Therapeutics Shares Jump
July 05, 2023
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones dropping around 100 points on Wednesday. The Dow traded down 0.30% to 34,316.70 while the NASDAQ fell 0.04% to 13,811.43....
Via
Benzinga
Crude Oil Rises Sharply; Impel Pharmaceuticals Shares Spike Higher
July 05, 2023
U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 50 points on Wednesday. The Dow traded down 0.17% to 34,361.31 while the NASDAQ fell 0.14% to 13,797.72. The S&P 500,...
Via
Benzinga
Recap: C4 Therapeutics Q1 Earnings
May 04, 2023
Via
Benzinga
Where C4 Therapeutics Stands With Analysts
March 28, 2023
Via
Benzinga
Looking Into C4 Therapeutics's Return On Capital Employed
February 28, 2023
Via
Benzinga
Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
July 05, 2023
Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares surged 87% to $11.78 after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in...
Via
Benzinga
C4 Therapeutics Inc. (NASDAQ: CCCC) is One of Wednesday Morning’s Most Active Stocks
July 05, 2023
Via
Investor Brand Network
Dow Drops 150 Points; US Factory Orders Increase 0.3% In May
July 05, 2023
U.S. stocks traded lower this morning, with the Dow Jones dropping over 150 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.46% to 34,259.45 while the NASDAQ fell...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
July 05, 2023
Via
Benzinga
C4 Therapeutics Stock Is Surging: What's Going On?
July 05, 2023
C4 Therapeutics Inc (NASDAQ: CCCC) shares are rising Wednesday after the clinical-stage biopharmaceutical company announced the FDA cleared its investigational new drug (IND)
Via
Benzinga
C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer
July 05, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer
June 20, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Week In Review: Betta Pharma Enters $392 Million Deal For C4 Therapeutics’ NSCLC Drug
June 03, 2023
Hangzhou Betta Pharma acquired greater China rights for a novel non-small cell lung cancer drug from Boston’s C4 Therapeutics in a deal worth up to $392 million. Additionally, Lynk Pharma of Hangzhou...
Via
Talk Markets
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
June 02, 2023
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
Via
Investor's Business Daily
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC
May 30, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 04, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
April 19, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2023
February 24, 2023
Via
Benzinga
Why Fulcrum Therapeutics Shares Are Trading Lower By Over 55%? Here Are Other Stocks Moving In Friday's Mid-Day Session
February 24, 2023
Gainers Bridger Aerospace Group Holdings, Inc. (NASDAQ: BAER) shares jumped 129.6% to $10.15. Jeffrey E. Kelter reported a 22.4% stake in a 13D filing on Thursday.
Via
Benzinga
C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
February 23, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Present at Two Virtual February 2023 Conferences
February 08, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.